F. Turner's scientific contributions

... CYP2B6 983T>C occurs predominantly in African subjects, with allele frequencies of 4% to 11% [19,20]. Homozygosity for the mutant allele CYP2B6 983 CC was not detected in this population, in concurrence with a previous study [25]. However, heterozygosity for the mutation CYP2B6 983TC was associated with higher plasma nevirapine levels in our study, with heterozygous TC individuals having levels 55% higher than those with the wild type TT. ...

... 21,22 Numerous studies have reported significant correlation of CYP2B6 c.516G > T genotype (CYP2B6*6), a decreased function allele, and c.983 T > C genotype (CYP2B6*18), a no function allele, or a genotype that is based on the two polymorphisms hereafter referred to as the "composite CYP2B6 c.516/983 or (CYP2B6*6/*18)" with plasma nevirapine levels. [23][24][25][26][27][28][29] However, only a limited number of studies have reported influence of both genotypes on CD4+ T lymphocytes counts and HIV RNA levels. 25,27, 28 We previously reported influence of composite CYP2B6*6/*18 genotype on the pharmacokinetics of nevirapine in the presence of artemether-lumefantrine in a subgroup of 30 HIV-infected patients 30 The present retrospective study evaluates the influence of composite CYP2B6*6/*18 genotype on the trough plasma nevirapine (the concentration immediately before the next dose is administered), and HIV RNA (virologic response) levels as well as on the absolute lymphocyte and CD4+ T lymphocyte counts (immunologic responses) in genetically defined groups of HIV-infected adult Nigerian patients on nevirapine-based ART combinations. ...